Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum
Executive Summary
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."
You may also be interested in...
Emerging Markets Are Next Turn In Sanofi Consumer Health Growth
Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.
Emerging Markets Are Next Turn In Sanofi Consumer Health Growth
Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.
Returns From Sanofi Consumer Expansion Could Point To More
The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first quarter with the launch of OTC switch Xyzal Allergy and with further integration of OTC drug and vitamin brands recently acquired from Boehringer Ingelheim.